Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock (NCT06745206) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock
30 participantsStarted 2025-12
Plain-language summary
As infection control improves and circulation stabilizes, treatment de-escalation of septic shock begins, accompanied by fluid redistribution from interstitial spaces to the vasculature, increasing cardiac volume load. Synthetic recombinant human BNP (rh-BNP) plays a role in inducing vasodilation, particularly in the venous system, alleviating cardiac congestion, and enhancing natriuresis and diuresis. Thus the investigators designed a single-center, prospective physiological study to evaluate the efficacy of standard rh-BNP infusion in reducing venous return and enhancing fluid removal, with a secondary objective of assessing the maintenance of perfusion pressure and tissue perfusion.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age \>18 years.
✓. Septic shock in recovery phase with decreasing vasopressor requirements, which is defined as:
✓. Fulfilling the Sepsis-3 definition of septic shock at initial stage.
✓. Hemodynamic stability achieved after adequate initial resuscitation and individualized hemodynamic optimization.
✓. Controlled infection source with 48-hour trend of improving temperature, white blood cell count, and procalcitonin.
✓. 48-hour trend of decreasing vasopressor requirements and transition to negative fluid balance.
✓. Adequate perfusion with warm extremities, and capillary refill time \<3 seconds.
✓. Ongoing pulse index continuous cardiac output (PiCCO) hemodynamic monitoring and sinus rhythm.
Exclusion criteria
✕. Pregnancy or lactation.
✕
What they're measuring
1
The pressure gradient of venous return
Timeframe: From baseline to 30 minutes after rh-BNP initiation.